Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.

August 13, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Presentation. Further to our Letter dated August 10, 2026, we are enclosing herewith Investor Presentation with respect to the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026. Kindly take the information on record. Thanking you, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE SUPRIYA LIFESCIENCE LTD. SUPRIYA LIFESCIENCE LTD. Q1 FY27 Investor Presentation Safe Harbour SUPRIYA LIFESCIENCE LTD. This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward- looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q1 FY27 Highlights SUPRIYA LIFESCIENCE LTD. Q1 FY27 Highlights ylretrauQ ecnamrofreP lanoigeR SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT INR 1,897.5 Mn INR 474.6 Mn INR 407.9 Mn INR 240.4 Mn 31% YoY 8% YoY 14% YoY 31% YoY Business Mix Revenue Contribution – By Region 34% 35% Q1 FY26 17% 17% Q4 FY26 ■ Q1 FY27 6% ■ 4% 3% 4% 3% Asia Europe LATAM North America Others Q1 FY27 Y-o-Y Highlights SUPRIYA LIFESCIENCE LTD. (INRMn) Revenue EBITDA PBT PAT 31% YoY 8% YoY 14% YoY 31% YoY 1897.5 347.9 474.1 517.0 1450.7 240.4 474.6 407.9 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 EBITDA Margins PAT Margins 1,063 bps YoY 1,131 bps YoY 35.6% 24.0% 25.0% 12.7% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Business Mix Revenue Contribution – By Therapy SUPRIYA LIFESCIENCE LTD. Performance of the Top Therapeutic Areas 9% 9% - - 5% -4% - - 3% 3% 3% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive Q1FY26 Q1FY27 Profit & Loss Statement SUPRIYA LIFESCIENCE LTD. Particulars (in INR Mn) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q Revenue from Operations 1,897.5 1450.7 30.8% 2,765.3 -31.4% Cost of Goods Sold 563.9 317.7 77.5% 1053.3 -46.5% Employee Benefits Expense 284.9 226.9 25.6% 248.2 14.8% Other Expenses 574.1 389.1 47.5% 487.7 17.7% EBITDA 474.6 517.0 -8.2% 976.2 -51.4% EBITDA % 25.0% 35.6% -1,063 bps 35.3% -1,029 bps Other Income 26.5 26.7 -1.0% 34.8 -23.8% + +- + Depreciation and Amortisation Expense 89.4 64.5 38.6% 85.0 5.2% EBIT 411.7 479.2 -14.1% 926.0 -55.5% Finance Costs 3.7 5.1 -27.0% 4.7 -20.3% PBT 407.9 474.1 -14.0% 921.3 -55.7% Total Tax Expense 167.5 126.2 32.7% 179.0 -6.4% Profit for the year 240.4 347.9 -30.9% 742.3 -67.6% PAT % 12.7% 24.0% -1,131 bps 26.8% -1,417 bps EPS (INR) 2.99 4.32 9.22 Company Overview SUPRIYA LIFESCIENCE LTD. Business Overview SUPRIYA LIFESCIENCE LTD. Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ 120+ 35,000 932 APIs Countries Sq.mts KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity 40+ 1,500+ WHO-GMP, Written 81% Confirmation, ISO, Halal, Indonesian Halal. Fami QS Years of excellence in manufacturing customers Q1FY27 Revenue from exports m,) U.S. FOOD & DRUG - ADMINISTRATION ..._1 1-ilea!th Cfi)fepris ~ CONS[IL DI: L [l.ll.Of'( 4 Times approved 2 times approved "'I"'" Canada Ci:,m"51r,n F'~r.ll P,.VJ LJ Pnyl~tJ6ri comro Rio!:.aJ05-.Stllh~b~ • KFDA.• NMPA KoraaFood&DrugAdmlnlslrallon ■ae1u1■■•• ANVISA 2 Times approved Journey So Far SUPRIYA LIFESCIENCE LTD . 2022 2023 2024 2025 2026 CEP (Certificate of The Company commenced ANVISA Approval Launch of three Commercialized CMO suitability ) renewed for operations at its Granted molecules including facility at Ambernath Pheniramine Maleate, new R&D lab in Liquid Anesthesia 4th USFDA approval Chlorpheniramine Lote Parshuram received for Lote Facility Maleate and Ketamine Hydrochloridec -.- -.- -.- -.- 2021 2020 2018 2017 2015 2014 ~--• ----------• ----------• ----------• ----------• -----------· ---- CEP granted for Pentoxifylline, Third time CEP granted for CEP granted for EUGMP and EDQM USFDA approval Esketamine Hydrochloride and USFDA approval Brompheniramine Maleate, Pheniramine Maleate; approval granted granted; IDL granted for Salbutamol Sulphate; Mepyramine Maleate & Second time USFDA Brompheniramine Health Canada approval Ketamine Hydrochloride approval granted Maleate Listed on Stock Exchange BSE & NSE -.- -.- -.- 2008 2009 2010 2011 2013 ---------• ----------• ----------• ----------• -----------• ---~ Incorporation & Started production CEP granted for IDL granted for COFEPRIS and conversion from a of Ketamine Chlorphenamine Chlorphenamine KFDA partnership firm to a hydrochloride Maleate Maleate approval granted public limited company Backward Integrated Business Model SUPRIYA LIFESCIENCE LTD. Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential [Showing first 8,000 characters — download PDF for full document]